- Home
- SNTI vs SNAL Comparison
SNTI vs SNAL Comparison
Compare SNTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- SNAL
- Stock Information
- Founded
- SNTI 2016
- SNAL 2000
- Country
- SNTI United States
- SNAL United States
- Employees
- SNTI N/A
- SNAL N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- SNAL Computer Software: Prepackaged Software
- Sector
- SNTI Health Care
- SNAL Technology
- Exchange
- SNTI Nasdaq
- SNAL Nasdaq
- Market Cap
- SNTI 53.6M
- SNAL 45.1M
- IPO Year
- SNTI N/A
- SNAL 2022
- Fundamental
- Price
- SNTI $2.15
- SNAL $1.06
- Analyst Decision
- SNTI Strong Buy
- SNAL
- Analyst Count
- SNTI 3
- SNAL 0
- Target Price
- SNTI $9.67
- SNAL N/A
- AVG Volume (30 Days)
- SNTI 327.7K
- SNAL 97.1K
- Earning Date
- SNTI 11-13-2025
- SNAL 11-13-2025
- Dividend Yield
- SNTI N/A
- SNAL N/A
- EPS Growth
- SNTI N/A
- SNAL N/A
- EPS
- SNTI N/A
- SNAL N/A
- Revenue
- SNTI N/A
- SNAL $91,041,290.00
- Revenue This Year
- SNTI N/A
- SNAL $13.87
- Revenue Next Year
- SNTI $150.00
- SNAL $26.20
- P/E Ratio
- SNTI N/A
- SNAL N/A
- Revenue Growth
- SNTI N/A
- SNAL 24.25
- 52 Week Low
- SNTI $1.26
- SNAL $0.64
- 52 Week High
- SNTI $16.94
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- SNTI 62.17
- SNAL 49.42
- Support Level
- SNTI $1.92
- SNAL $0.96
- Resistance Level
- SNTI $2.29
- SNAL $1.20
- Average True Range (ATR)
- SNTI 0.25
- SNAL 0.07
- MACD
- SNTI 0.01
- SNAL 0.00
- Stochastic Oscillator
- SNTI 55.06
- SNAL 41.71
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.